Visitors hoping to take home something special for themselves or for those at home need look no farther than "The Magnificent Mile," the 1-mile stretch of North Michigan Avenue from the Chicago River on the south to Oak Street on the north.
FDA grants priority review to frontline enfortumab vedotin plus pembrolizumab for urothelial carcinoma
The priority review is based on results from the phase 3 EV-302 trial.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Cretostimogene grenadenorepvec hits high complete response rate in NMIBC
The oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses in over three-fourths of patients with high-risk BCG-unresponsive non–muscle-invasive bladder cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Neoadjuvant chemo confers greater odds of pCR in upper tract urothelial carcinoma
The investigators reported that pCR was significantly higher in the neoadjuvant chemotherapy + RNU group vs RNU alone, with an OR of 2.49 (95% CI: 1.75 – 3.54, P < .001).
PSMA-PET enhances management of oligometastatic prostate cancer
PSMA-PET is becoming an invaluable tool for the diagnosis and management of oligometastatic prostate cancer patients, a sub-group for whom novel treatment strategies are continuing to emerge.
2 Clarke Drive Cranbury, NJ 08512